28-Day Oral Chronic Toxicity Study of Arctigenin in Rats

Tan Y, Ren Y, Gao L, Li L, Cui L, Li B, Li X, Yang J, Wang M, Lv Y, Xu X, Yao J, Liu Z, Zhang G, Li J · Frontiers in Pharmacology · 2018 September 26

DOI 10.3389/fphar.2018.01077

Objective

To investigate the sub-chronic toxicity profile of Arctigenin in rats following 28 consecutive days of exposure.

Conclusions

Arctigenin caused dose-dependent and partly irreversible histopathological lesions, accumulated in rat organs, and had a lowest observed adverse effect level of 12 milligrams per kilogram per day, indicating that Arctium lappa should be consumed cautiously because its no-observed-adverse-effect level is lower than 12 milligrams per kilogram per day.

Critical Appraisal

Published research can offer valuable insights, but a paper’s conclusions may go beyond what its results support. Critical appraisal examines the methods, findings and limitations to clarify what can reasonably be concluded—and what remains uncertain.

This article has not yet been critically appraised by the Research Hub.

Learn more about Critical Appraisal

Insights

Arctigenin, a burdock compound, accumulated in rats and caused persistent multi-organ damage despite largely normal routine blood tests.

Rats received daily arctigenin exposure for four weeks at different dose levels, followed by a drug-free recovery period. Researchers assessed body and organ weights, food intake, blood and biochemical measures, tissue pathology, reproductive organs, and arctigenin distribution across organs. Arctigenin caused inflammatory, degenerative, and necrotic damage in the heart, kidneys, liver, lungs, pancreas, and reproductive tissues, with some changes persisting after treatment stopped. The compound accumulated in organs, while routine blood and biochemical measures often failed to reflect the tissue injury, highlighting a disconnect between standard clinical indicators and underlying organ toxicity.